Skip to main content
SpringerLink
Log in

Chemotherapie und zielgerichtete Therapie von Kopf-Hals-Plattenepithelkarzinomen beim ASCO-Kongress 2021

Chemotherapy and targeted therapy of head and neck squamous cell carcinomas at the 2021 ASCO meeting

  • Leitthema
  • Published:
HNO Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Bei der Konferenz der American Society of Clinical Oncology (ASCO) 2021 wurde Neues rund um Chemotherapien und zielgerichtete Therapien vorgestellt. im vorliegenden Beitrag werden einige dieser Publikationen zusammengefasst.

Ziel der Arbeit

Relevante Publikationen werden zusammenfasst dargestellt und bewertet.

Methoden

Über eine Datenbankabfrage wurden Abstracts des diesjährigen ASCO-Kongresses gesucht, die sich mit Chemotherapie oder zielgerichteten Therapien bei Kopf-Hals-Plattenepithelkarzinomen beschäftigten. Forschungsankündigungen ohne Daten sowie Publikationen mit Überschneidung zu den weiteren Artikeln dieser Ausgabe wurden aussortiert.

Ergebnisse

Die Autor*innen stellen 6 Artikel weiterführend vor. Hierbei geht es um neue Applikationsformen sowie die Dosisfindung bei Cisplatin. Zudem geht es um Neoadjuvanzien sowie Cetuximab nach Immuntherapie. Neu untersucht werden liposomales Irinotecan und der mHRAS-Inhibitor Tipifarnib.

Schlussfolgerung

Patientenspezifischere Dosierungen von Cisplatin sowie die lokale Applikation könnten in Zukunft von Bedeutung sein. Die Blockade von mHRAS wird im Einzelfall nach Sequenzierung Nutzen finden.

Abstract

Background

This article summarizes new findings on chemo- and targeted therapy of head and neck squamous cell carcinoma presented at the 2021 American Society of Clinical Oncology (ASCO) conference.

Objective

Relevant publications were evaluated and summarized.

Methods

The abstract database of the 2021 ASCO conference was searched. Publications were selected if they focused on chemo- or targeted therapies in head and neck squamous cell carcinoma. Publications covered in other articles of this issue were omitted, as were study proposals without results.

Results

The authors present six articles. Dosage and novel forms of application are shown for cisplatin. Cetuximab is used in the neoadjuvant setting and for progressive disease following immune therapy. Lastly, two new drugs in the form of liposomal irinotecan and the mHRAS inhibitor tipifarnib are discussed.

Conclusion

Patient-specific and possibly local application of cisplatin might be considered in the future. Moreover, mHRAS inhibition might also be useful for selected patients after sequencing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Harrington KJ, Rischin D, Greil R et al (2020) KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 38:6505–6505. https://doi.org/10.1200/jco.2020.38.15_suppl.6505

    Article  Google Scholar 

  2. Guigay J et al (2021) Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 22:463–475

    Article  CAS  Google Scholar 

  3. Mascarella MA, Vendra V, Kubik M et al (2021) Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma. J Clin Oncol 39:6033–6033. https://doi.org/10.1200/jco.2021.39.15_suppl.6033

    Article  Google Scholar 

  4. Amin N, Maroun CA, Asmar ME et al (2022) Neoadjuvant immunotherapy prior to surgery for mucosal head and neck squamous cell carcinoma: systematic review. Head Neck 44:562–571. https://doi.org/10.1002/hed.26935

    Article  PubMed  Google Scholar 

  5. Molenaar-Kuijsten L, Chargi N, Devriese L et al (2021) The association of skeletal muscle mass and cisplatin pharmacokinetics in head and neck cancer patients: The prospective PLATISMA study. J Clin Oncol 39:6021–6021. https://doi.org/10.1200/jco.2021.39.15_suppl.6021

    Article  Google Scholar 

  6. Wendrich AW, Swartz JE, Bril SI et al (2017) Low skeletal muscle mass is a predictive factor for chemotherapy dose-limiting toxicity in patients with locally advanced head and neck cancer. Oral Oncol 71:26–33. https://doi.org/10.1016/j.oraloncology.2017.05.012

    Article  CAS  PubMed  Google Scholar 

  7. Agrawal N, Izumchenko E, Hodge K et al (2021) A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC). J Clin Oncol 39:6056–6056. https://doi.org/10.1200/jco.2021.39.15_suppl.6056

    Article  Google Scholar 

  8. Cohen SM, Rockefeller N, Mukerji R et al (2013) Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg 139:382–387. https://doi.org/10.1001/jamaoto.2013.214

    Article  PubMed  PubMed Central  Google Scholar 

  9. Issa M, Klamer B, Karivedu V et al (2021) Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors. J Clin Oncol 39:6038–6038. https://doi.org/10.1200/jco.2021.39.15_suppl.6038

    Article  Google Scholar 

  10. Bai L‑Y, Yang M‑H, Chiang N‑J et al (2021) A phase 2 study of liposomal irinotecan with 5‑fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy. J Clin Oncol 39:6025–6025. https://doi.org/10.1200/jco.2021.39.15_suppl.6025

    Article  Google Scholar 

  11. Haddad RI, Adkins D, Licitra LF et al (2021) The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with HRAS mutations. J Clin Oncol 39:TPS6087–TPS6087. https://doi.org/10.1200/jco.2021.39.15_suppl.tps6087

    Article  Google Scholar 

  12. Ho AL, Brana I, Haddad R et al (2021) Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol 39:1856–1864. https://doi.org/10.1200/jco.20.02903

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für HNO-Heilkunde, Kopf- und Halschirurgie, Universitätsmedizin Greifswald, Ferdinand Sauerbruch Str. 1, 17475, Greifswald, Deutschland

    Markus Blaurock & Chia-Jung Busch

Authors
  1. Markus Blaurock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chia-Jung Busch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Blaurock.

Ethics declarations

Interessenkonflikt

C.-J. Busch gibt folgende Interessenkonflikte an: Honorar für Vortragstätigkeiten und Advisory Board von BMS, Merck, MSD und GSK. Fördergelder von BMS. M. Blaurock gibt an, dass keine Interessenkonflikte bestehen.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blaurock, M., Busch, CJ. Chemotherapie und zielgerichtete Therapie von Kopf-Hals-Plattenepithelkarzinomen beim ASCO-Kongress 2021. HNO 70, 265–270 (2022). https://doi.org/10.1007/s00106-022-01152-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00106-022-01152-2

Schlüsselwörter

Keywords

Search

Navigation